Skip to search formSkip to main contentSkip to account menu

MK 0852

Known as: MK 852, MK-852, MK-0852 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Cyclic PeptidesOligopeptidesThiazolidines
L 367073

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist
This study was to investigate the appearance of P-selectin, tissue factor (TF) and CD40 ligand (CD40L) on platelet-leucocyte… 
2000
2000
Antiplatelet Effects of MK‐852, a Platelet Fibrinogen Receptor Antagonist, in Healthy Volunteers
MK‐852, a cyclic heptapeptide, is a potent platelet fibrinogen receptor antagonist When administered to normal healthy male… 
1996
1996
Changes in the composition of the platelet cytoskeleton in response to ADP: effects of MK-852 and ARL 66096.
Platelet activation by adenosine diphosphate (ADP) results in an alteration in the composition of the cytoskeleton. Here we have… 
1996
1996
Dose-responses to inducers and inhibitors of platelet aggregation analysed via a micro-method.
The ex vivo study of platelet function in small experimental animals treated with anti-platelet drugs is restricted by the… 
1996
1996
The composition of the platelet cytoskeleton following activation by ADP: effects of various agents that modulate platelet function.
Platelet activation by adenosine diphosphate (ADP) results in changes in the composition of the large cytoskeletal fragments that… 
1995
1995
Kinetics of Free Platelet Decrease After ADP: Effect of Fibrinogen Binding Inhibitors.
Evaluation of platelet aggregation in vitro has generally been performed by the turbidometric method. This technique is largely… 
1994
1994
Inhibition of fibrinogen binding to platelets by MK-852, a new GPIIb/IIIa antagonist.
MK-852 is a newly developed low molecular weight inhibitor of fibrinogen binding to platelets. Platelet aggregation and adhesion… 
1993
1993
Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)